2013


To access this material please log in or register

Register Authorize
2013/№4

Angiotensin II receptor antagonists in cardiology: heading for organ protection

Timofeeva N. Yu., Snetkova A. A., Zadionchenko V. S.

Keywords: angiotensin ii receptor antagonists, organ protection, cardiovascular diseases

DOI: 10.18087/rhj.2013.4.1769

At the present time, ARAs including irbesartran and its generic ibetran completely similar to the original drug in bioequivalence, bioavailability and pharmacokinetic properties, take one of the leading places in the treatment of AH, post-MI conditions, and CHF. The indisputable organ-protective effects documented by clinical studies make irbesartran (ibertran) the drug of choice in renal injury (microalbuminuria / proteinuria, diabetic nephropathy with chronic renal disease), LV myocardial hypertrophy, metabolic syndrome, and atrial fibrillation.
  1. Преображенский Д. В., Сидоренко Б. А., Романова Н. Е., Шатунова И. М. Клиническая фармакология основных классов антигипертензивных препаратов. Cons. Med. 2002;2 (3):99–127.
  2. Карпов Ю. А. Столетний юбилей открытия ренина. Клинич. фармакол. и тер. 1998;7 (8):46–49.
  3. Pals DT, Masucci FD, Sipos F, Denning GS Jr. A specific competitive antagonist of the vascular action of angiotensin II. Circ Res. 1971;29 (6):664–672.
  4. Ferreiro SH. History of the development of inhibitors of angiotensin I conversion. Drugs. 1985;30 (Suppl 1):1–5.
  5. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J. 1994;127 (5):1388–1401.
  6. Chung O, Csikós T, Unger T. Angiotensin II receptor pharmacology and AT1‑receptor blockers. J Hum Hypertens. 1999;13 (Suppl 1):S11–20.
  7. De Leeuw PW. How do angiotensin II receptors antagonist affect blood pressure? Am J Cardiol. 1999;13 (1):5–6.
  8. Диагностика и лечение артериальной гипертонии. Российские рекомендации (третий пересмотр) 2008 г. Кардиоваскулярная терапия и профилактика. 2008;6 (Приложение 2).Доступно на: www.cardiosite.ru / recommendations / 2008.
  9. Lindholm LH, Ibsen H, Dahlof B et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359 (9311):995–1003.
  10. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345 (12):861–869.
  11. Schrader J, Luders S, Kulschewski A et al. Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomi­zed controlled study (MOSES). Stroke. 2005;36 (6):1218–1226.
  12. Lithell H, Hansson L, Skoog I et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21 (5):875–886.
  13. Matchar DB, McCrory DC, Orlando LA et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibi­tors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148 (1):16–29.
  14. Nixon RM, Müller E, Lowy A, Falvey H. Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach. Int J Clin Pract. 2009;63 (5):766–775.
  15. Bramlage P, Durand-Zaleski I, Desai N et al. The valie of irbesartan in the management of hypertension. Expert Opin Pharmacother. 2009;10 (11):1817–1831.
  16. Kassler-Taub K, Littlejohn T, Elliott W et al. Comparative efficacy of two angiotensin II receptor antagonists, irbesartan and losartan in mild-to-moderate hypertension. Irbesartan / Losartan Study Investigators. Am J Hypertens. 1998;11 (4 Pt 1):445–453.
  17. Oparil S, Guthrie R, Lewin AJ et al. An elective-titration study ofthe comparative effectiveness of two angiotensin II-receptor blockers,irbesartan and losartan. Irbesartan / Losartan Study Investigators. Clin Ther. 1998;20 (3):398–409.
  18. Bramlage P, Hasford J. Blood pressure reduction, persistence and costs in the evaluation of antihypertensive drug treatment – a review. Cardiovasc Diabetol. 2009;8:18.
  19. Petrella R, Michailidis P. Retrospective analysis of real-world efficacy of angiotensin receptor blockers versus other classes of antihypertensive agents in blood pressure management. Clin Ther. 2011; 33 (9):1190–1203.
  20. Malmqvist K, Kahan T, Edner M et al. Regression of left ventricular hypertrophy in human hypertension with irbesartan. J Hypertens. 2001;19 (6):1167–1176.
  21. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25 (6):1105–1187.
  22. Швецов М. Ю., Медведева Т. Ю., Оконова Е. Б. и др. Блокаторы ангиотензиновых рецепторов 1 типа – новый класс нефропротективных препаратов. Клинич. фармакол. Тер. 2002;11 (2):62–69.
  23. Taal MW, Brenner BM. Combination ACEI and ARB therapy: additional benefit in renoprotection? Curr Opin Nephrol Hypertens. 2002;11 (4):377–381.
  24. Parving HH, Lehnert H, Brochner-Martensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345 (12):870–878.
  25. Palmer AJ, Annemans L, Roze S et al. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings. Nephrol Dial Transplant. 2003;18 (10):2059–2066.
  26. Coronel F, Cigarrán S, García-Mena M et al. Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI. Nefrologia. 2008;28 (1):56–60.
  27. Schupp M, Janke J, Clasen R et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation. 2004;109 (17):2054–2057.
  28. Kintscher U, Bramlage P, Paar WD et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients. Cardiovasc Diabetol. 2007;6:12.
  29. Morawietz H, Erbs S, Holtz J et al. Endothelial Protection, AT1 blockade and Cholesterol-Dependent Oxidative Stress: the EPAS trial. Circulation. 2006;114 (1 Suppl): I296–301.
  30. Sola S, Mir MQ, Cheema FA et al. Irbesartan and lipoic acid improve endothelial function and reduce markers of inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) study. Circulation. 2005;111 (3):343–348.
  31. Fogari R, Ambrosoli S, Corradi L et al. 24‑hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring: Irbesartan Multicenter Investigators Group. J Hypertens. 1997;15 (12 Pt 1):1511–1518.
  32. Yusuf S, Healey JS, Pogue J et al. ACTIVE I Investigators. Irbesartan in patients with atrial fibrillation. N Engl J Med. 2011;364 (10):928–938.
  33. Национальные рекомендации ВНОК и ОССН по диагностике и лечению ХСН (третий пересмотр). Журнал Сердечная Недостаточность. 2010;11 (1):3–62.
  34. Massie BM, Carson PE, McMurray JJ et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359 (23):2456–2467.
  35. Braumhakel M, Schlimmer N, Bohm M. Effect of irbesartan on erectile Function in patients with hypertension and metabolic syndrome. Int J Impot Res. 2008;20 (5):493–500.
Timofeeva N. Yu., Snetkova A. A., Zadionchenko V. S. Angiotensin II receptor antagonists in cardiology: heading for organ protection. Russian Heart Journal. 2013;12(4):236-242

To access this material please log in or register

Register Authorize
Ru En